PERCIVIA provides technology transfer and technical support to the users of PER.C6® platform throughout the world.

PERCIVIA is the joint venture between DSM Biologics (a division of DSM Pharmaceuticals www.dsm.com), a leading contract manufacturing organization for the pharmaceutical industry, and Crucell N.V. (www.crucell.com), a biotechnology company developing vaccine and recombinant protein products. Both companies have joined forces to promote the use of the PER.C6® platform for the large-scale production of recombinant therapeutic proteins.

Management

Marco Cacciuttolo, Chief Executive Officer of PERCIVIA
Dr. Cacciuttolo has over ten years of experience in technical operations within the biotech and pharmaceutical industries. He has occupied positions of increasing responsibility at MedImmune, Inc., and most recently at Medarex, Inc. as the Vice President of Technical Operations. Dr. Cacciuttolo received his Ph.D. in Biochemical Engineering from the University of Maryland, Baltimore County and his B.S. in Biochemical Engineering from the Catholic University of Valparaiso, Valparaiso, Chile.